Complexa Inc., of Pittsburgh, disclosed completion of an extensive phase I development program for its lead compound, CXA-10, an endogenous nitro-fatty acid modulator of Nrf2 and NF-κB, which is designed to impact the core of fibrotic and inflammatory pathways.